A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07664553

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07664553
  • EU CT 2025-523935-20-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Bulgaria, Canada, China, Czechia, Germany, India, Japan, Malaysia, Poland, South Korea, Thailand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07664553. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2028-05-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Acronym
Eluminate-3
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07664553
Content hash
79a580c9e31a413947d81246d3fa290a648efbd3d908621da80b09cfad9564c4